The standard therapy for AML has not changed significantly in the past 40 years.6,8
- Induction therapy with 7+3 combination chemotherapy (7 days of cytarabine and 3 days of an anthracycline)
- Followed by consolidation therapy to maintain remission (high-dose chemotherapy and allogeneic bone marrow transplant)
Outcomes remain poor, with high rates of relapse for most patients. Older patients pose a difficult therapeutic challenge due to comorbidities and poor performance status, which make them ineligible for intensive therapy.14
Recent additions to the armamentarium are based on cytogenetic or mutation profiles and may only benefit certain patients due to the heterogeneity of the disease.